However, LZP deficiency attenuates apoB-mediated VLDL secretion, leading to lower serum apoB and TG levels in mice; therefore, LZP could be considered a potential therapeutic target for hyperlipemia, especially hypertriglyceridemia. Here, OIT3 is linked to familial hyperlipidemia.